PART II ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES Our common stock is listed on the New York Stock Exchange under the symbol "APD. "
As of 31 October 2019, there were 5,166 record holders of our common stock.
Cash dividends on the Company’s common stock are paid quarterly.
It is our expectation that we will continue to pay cash dividends in the future at comparable or increased levels.
The Board of Directors determines whether to declare dividends and the timing and amount based on financial condition and other factors it deems relevant.
Dividend information for each quarter of fiscal years 2019 and 2018 is summarized below:
## Table 0 ##
Purchases of Equity Securities by the Issuer On 15 September 2011, the Board of Directors authorized the repurchase of up to $1.0 billion of our outstanding common stock.
This program does not have a stated expiration date.
We repurchase shares pursuant to Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934, as amended, through repurchase agreements established with one or more brokers.
There were no purchases of stock during fiscal year 2019.
At 30 September 2019, $485.3 million in share repurchase authorization remained.
Additional purchases will be completed at the Company’s discretion while maintaining sufficient funds for investing in its businesses and growth opportunities.
Bristol-Myers Squibb 40 Otsuka BMS has a worldwide commercialization agreement with Otsuka Pharmaceutical Co. , Ltd.  (Otsuka), to codevelop and copromote Abilify, for the treatment of schizophrenia, bipolar mania disorder and major depressive disorder, excluding certain Asia Pacific countries.
The U. S.  portion of the amended commercialization and manufacturing agreement expires upon the expected loss of product exclusivity in April 2015.
The contractual share of Abilify net sales recognized by BMS was 65% in 2009, 58% in 2010 and 53.5% in 2011.
Beginning on January 1, 2012, the contractual share of revenue recognized by BMS was further reduced to 51.5%.
In the UK, Germany, France and Spain, BMS receives 65% of third-party net sales.
In these countries and the U. S. , third-party customers are invoiced by BMS on behalf of Otsuka and alliance revenue is recognized when Abilify is shipped and all risks and rewards of ownership have transferred to third party customers.
In certain countries where BMS is presently the exclusive distributor for the product or has an exclusive right to sell Abilify, BMS recognizes all of the net sales.
BMS purchases the product from Otsuka and performs finish manufacturing for sale to third-party customers by BMS or Otsuka.
Under the terms of the amended agreement, BMS paid Otsuka $400 million, which is amortized as a reduction of net sales through the expected loss of U. S.  exclusivity in April 2015.
The unamortized balance is included in other assets.
Otsuka receives a royalty based on 1.5% of total U. S.  net sales, which is included in cost of products sold.
Otsuka is responsible for 30% of the U. S.  expenses related to the commercialization of Abilify from 2010 through 2012.
Reimbursements are netted principally in marketing, selling and administrative and advertising and product promotion expenses.
Beginning January 1, 2013, and through the expected loss of U. S.  exclusivity in April 2015, including an expected six month pediatric extension, BMS will receive the following percentages of U. S.  annual net sales:
## Table 1 ##
During this period, Otsuka will be responsible for 50% of all U. S.  expenses related to the commercialization of Abilify.
BMS and Otsuka also entered into an oncology collaboration for Sprycel and Ixempra for the U. S. , Japan and European Union (EU) markets (the Oncology Territory).
A collaboration fee, classified in cost of products sold, is paid to Otsuka based on the following percentages of annual net sales of Sprycel and Ixempra in the Oncology Territory:
## Table 2 ##
During these periods, Otsuka contributes (i) 20% of the first $175 million of certain commercial operational expenses relating to the oncology products, and (ii) 1% of such commercial operational expenses relating to the products in the territory in excess of $175 million.
Beginning in 2011, Otsuka copromotes Sprycel in the U. S.  and Japan, and has exercised the right to copromote in the top five EU markets beginning in January 2012.
The U. S.  extension and the oncology collaboration include a change-of-control provision in the case of an acquisition of BMS.
If the acquiring company does not have a competing product to Abilify, then the new company will assume the Abilify agreement (as amended) and the oncology collaboration as it exists today.
If the acquiring company has a product that competes with Abilify, Otsuka can elect to request the acquiring company to choose whether to divest Abilify or the competing product.
In the scenario where Abilify is divested, Otsuka would be obligated to acquire the rights of BMS under the Abilify agreement (as amended).
The agreements also provide that in the event of a generic competitor to Abilify after January 1, 2010, BMS has the option of terminating the Abilify April 2009 amendment (with the agreement as previously amended remaining in force).
If BMS were to exercise such option then either (i) BMS would receive a payment from Otsuka according to a pre-determined schedule and the oncology collaboration would terminate at the same time or (ii) the oncology collaboration would continue for a truncated period according to a pre-determined schedule.
Gas Sales and Deliveries O&R generally recovers the cost of the gas that it buys and then sells to its firm sales customers.
It does not make any margin or profit on the gas it sells.
O&R’s gas revenues are subject to a weather normalization clause.
Effective November 2009, O&R’s New York gas revenues (which accounted for substantially all of O&R’s gas revenues in 2009) became subject to a revenue decoupling mechanism.
As a result, its gas delivery revenues are generally not affected by changes in delivery volumes from levels assumed when rates were approved.
O&R’s gas deliveries and sales for the last five years were
## Table 3 ##
For further discussion of the company’s gas operating revenues and its gas results, see “Results of Operations” in Item 7.
For additional segment information, see Note N to the financial statements in Item 8.
Gas Peak Demand The gas peak demand for firm service customers in O&R’s service area occurs during the winter heating season.
The daily peak day demand during the winter 2009/2010 (through January 31, 2010) occurred on January 3, 2010 when the demand reached 169 mdths.
The 2009/2010 winter demand included an estimated 81 mdths for O&R’s full-service customers and 88 mdths for customers participating in its gas retail access program.
“Design weather” for the gas system is a standard t which the actual peak demand is adjusted for evaluation and planning purposes.
The company estimates that under design weather conditions the 2010/2011 service area peak demand will be 216 mdths, including an estimated 101 mdths for its full- service customers and 115 mdths for its retail access customers.
The company forecasts average annual growth of the peak gas demand over the next five years at design conditions to be approximately 0.6 percent in the company’s service area.
The forecasted peak demand at design conditions does not include gas used by interruptible gas customers or in generating stations.
The company continues to monitor the potential impact on customer demand from the continuing difficult economic conditions.
The services we currently provide include collection, landfill (solid and hazardous waste landfills), transfer, recycling and resource recovery and other services, as described below.
The following table shows revenues (in millions) contributed by these services for the years ended December 31:

<table><tr><td></td><td>2019</td><td>2018</td></tr><tr><td>First quarter</td><td>$1.10</td><td>$.95</td></tr><tr><td>Second quarter</td><td>1.16</td><td>1.10</td></tr><tr><td>Third quarter</td><td>1.16</td><td>1.10</td></tr><tr><td>Fourth quarter</td><td>1.16</td><td>1.10</td></tr><tr><td>Total</td><td>$4.58</td><td>$4.25</td></tr></table>
<table><tr><td></td><td> Share as a % of U.S. Net Sales</td></tr><tr><td>$0 to $2.7 billion</td><td>50%</td></tr><tr><td>$2.7 billion to $3.2 billion</td><td>20%</td></tr><tr><td>$3.2 billion to $3.7 billion</td><td>7%</td></tr><tr><td>$3.7 billion to $4.0 billion</td><td>2%</td></tr><tr><td>$4.0 billion to $4.2 billion</td><td>1%</td></tr><tr><td>In excess of $4.2 billion</td><td>20%</td></tr></table>
<table><tr><td></td><td colspan="2"> % of Net Sales</td></tr><tr><td></td><td> 2010 - 2012</td><td> 2013 - 2020</td></tr><tr><td>$0 to $400 million</td><td>30%</td><td>65%</td></tr><tr><td>$400 million to $600 million</td><td>5%</td><td>12%</td></tr><tr><td>$600 million to $800 million</td><td>3%</td><td>3%</td></tr><tr><td>$800 million to $1.0 billion</td><td>2%</td><td>2%</td></tr><tr><td>In excess of $1.0 billion</td><td>1%</td><td>1%</td></tr></table>
<table><tr><td></td><td colspan="5"> Year Ended December 31,</td></tr><tr><td></td><td> 2005</td><td> 2006</td><td> 2007</td><td> 2008</td><td> 2009</td></tr><tr><td> Gas delivered (mDTH)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Firm Sales</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Full service</td><td>11,576</td><td>9,650</td><td>10,835</td><td>9,884</td><td>9,561</td></tr><tr><td>Firm transportation</td><td>9,841</td><td>9,058</td><td>10,248</td><td>10,471</td><td>10,905</td></tr><tr><td> Total Firm Sales and Transportation</td><td>21,417</td><td>18,708</td><td>21,083</td><td>20,355</td><td>20,466</td></tr><tr><td>Interruptible Sales</td><td>2,978</td><td>2,600</td><td>2,652</td><td>2,567</td><td>2,390</td></tr><tr><td> Total Gas Sold To O&R Customers</td><td>24,395</td><td>21,308</td><td>23,735</td><td>22,922</td><td>22,856</td></tr><tr><td>Transportation of customer-owned gas</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Interruptible transportation</td><td>3,480</td><td>3,256</td><td>3,331</td><td>2,842</td><td>2,112</td></tr><tr><td>Sales for resale</td><td>1,072</td><td>939</td><td>1,044</td><td>1,007</td><td>953</td></tr><tr><td>Sales to electric generating stations</td><td>1,434</td><td>3,036</td><td>4,552</td><td>2,327</td><td>1,346</td></tr><tr><td>Off-System Sales</td><td>172</td><td>372</td><td>455</td><td>249</td><td>624</td></tr><tr><td> Total Sales and Transportation</td><td>30,553</td><td>28,911</td><td>33,117</td><td>29,347</td><td>27,891</td></tr><tr><td> Gas delivered ($ in millions)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Firm Sales</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Full service</td><td>$161</td><td>$166</td><td>$186</td><td>$172</td><td>$159</td></tr><tr><td>Firm transportation</td><td>32</td><td>32</td><td>39</td><td>45</td><td>51</td></tr><tr><td> Total Firm Sales and Transportation</td><td>193</td><td>198</td><td>225</td><td>217</td><td>210</td></tr><tr><td>Interruptible Sales</td><td>29</td><td>28</td><td>25</td><td>27</td><td>21</td></tr><tr><td> Total Gas Sold To O&R Customers</td><td>222</td><td>226</td><td>250</td><td>244</td><td>231</td></tr><tr><td>Transportation of customer-owned gas</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sales to electric generating stations</td><td>2</td><td>3</td><td>3</td><td>4</td><td>2</td></tr><tr><td>Other operating revenues</td><td>4</td><td>7</td><td>12</td><td>10</td><td>9</td></tr><tr><td> Total Sales and Transportation</td><td>$228</td><td>$236</td><td>$265</td><td>$258</td><td>$242</td></tr><tr><td> Average Revenue Per DTH Sold</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Residential</td><td>$14.07</td><td>$17.38</td><td>$17.31</td><td>$17.64</td><td>$16.86</td></tr><tr><td> General</td><td>$13.37</td><td>$16.44</td><td>$16.36</td><td>$16.55</td><td>$15.58</td></tr></table>

Question: What is the percentage of all Firm Sales that are positive to the total amount, in 2005 for Gas delivered (mDTH)?
Answer: 1